OPTIONS GRANTED
Oslo, Norway (19 February 2020) — Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 29th, 2019, and the option program related to defined operational objectives approved by the Board of Directors in 2019, the Board of Directors of NattoPharma has in board proceedings February 18th, 2020 granted a total of 155 000 options to executive management, other employees and strategic partners. Options are granted based on performance against defined criteria and metrics.
The following persons on the executive management team have been granted options;
| Name | Shares Owned | Granted Options | Options Prior to Grant | Options after Grant |
| Kjetil Ramsøy, CEO & CFO | 300 000 | 50 000 | 225 100 | 275 100 |
Other employees and partners have been granted a total of 105 000 options.
The options have an exercise price equal the closing price on Oslo Axess on February 18th, 2020, which is equal to NOK 9,20. The options granted are vested immediately and may be exercised up to and including March 31st, 2023.
Further, in conjunction with the hiring of the new Chief Financial Officer in NattoPharma the Board of Directors has in board proceedings February 18th, 2020 granted a total of 30,000 options to Robert Schrama who will start in the new position on March 9th, 2020. Mr. Schrama holds no shares or options in NattoPharma ASA prior to this grant. His total holding of shares and options following this grant is 30,000 options.
The options will have an exercise price equal the closing price on Oslo Axess on March 9th, 2020. The options granted are fully vested on September 9th, 2020 and may be exercised up to and including March 31st, 2023.
X X X
For more information, please contact:
Kjetil Ramsøy,
CEO, NattoPharma
E-mail: kjetil.ramsoy@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.